Myocardial Ischemia - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myocardial Ischemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Myocardial Ischemia - Pipeline Review, H2 2016', provides an overview of the Myocardial Ischemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia
- The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Myocardial Ischemia Overview 8
Therapeutics Development 9
Pipeline Products for Myocardial Ischemia - Overview 9
Pipeline Products for Myocardial Ischemia - Comparative Analysis 10
Myocardial Ischemia - Therapeutics under Development by Companies 11
Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes 12
Myocardial Ischemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Myocardial Ischemia - Products under Development by Companies 16
Myocardial Ischemia - Products under Investigation by Universities/Institutes 17
Myocardial Ischemia - Companies Involved in Therapeutics Development 18
Bayer AG 18
Cellmid Limited 19
CohBar, Inc. 20
Lixte Biotechnology Holdings, Inc. 21
Miltenyi Biotec GmbH 22
NoNO, Inc. 23
Shire Plc 24
Symic Biomedical, Inc. 25
Taxus Cardium Pharmaceuticals Group Inc. 26
ViroMed Co., Ltd. 27
Myocardial Ischemia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AB-002 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Alda-1 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
alferminogene tadenovec - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AntimiR-199a - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
BAY-606583 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CMK-103 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
EP-80317 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Humanin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
LB-100 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Peptagon - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
PMC-6 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
SB-030 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Stem Cell Therapy for Cardiovascular Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
VM-202 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Myocardial Ischemia - Dormant Projects 68
Myocardial Ischemia - Discontinued Products 69
Myocardial Ischemia - Product Development Milestones 70
Featured News & Press Releases 70
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 70
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 71
Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 72
Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 72
Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 73
Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 73
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 74
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 76
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 78
Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 78
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition 79
Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease 80
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 82
Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Number of Products under Development for Myocardial Ischemia, H2 2016 9
Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Myocardial Ischemia - Pipeline by Bayer AG, H2 2016 18
Myocardial Ischemia - Pipeline by Cellmid Limited, H2 2016 19
Myocardial Ischemia - Pipeline by CohBar, Inc., H2 2016 20
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 21
Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2016 22
Myocardial Ischemia - Pipeline by NoNO, Inc., H2 2016 23
Myocardial Ischemia - Pipeline by Shire Plc, H2 2016 24
Myocardial Ischemia - Pipeline by Symic Biomedical, Inc., H2 2016 25
Myocardial Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016 26
Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H2 2016 27
Assessment by Monotherapy Products, H2 2016 28
Number of Products by Stage and Target, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Myocardial Ischemia - Dormant Projects, H2 2016 68
Myocardial Ischemia - Discontinued Products, H2 2016 69